Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 1

Status

Terminated 4Recruiting 4Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Neoplasm Metastasis 2Stomach Neoplasms 1Endometrial Neoplasms 1Breast Neoplasms 1Advanced and Metastatic Urothelial Cancer 1

Interventions

Cyclophosphamide 166Docetaxel 154Bevacizumab 153Carboplatin 148Gemcitabine 146Cisplatin 146pembrolizumab 142Radiotherapy 135Paclitaxel 132Capecitabine 122Rituximab 115Oxaliplatin 104Fluorouracil 103Nivolumab 94Irinotecan 85Doxorubicin 85Pemetrexed 83Leucovorin 82Dexamethasone 82fludarabine 74fludarabine phosphate 72Bortezomib 69Etoposide 67Erlotinib Hydrochloride 66Cetuximab 65Methotrexate 58Trastuzumab 56Cytarabine 54Lenalidomide 50Everolimus 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Terminated × futibatinib × Clear all
NCT05036681 2026-03-27

A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma

M.D. Anderson Cancer Center

Phase 2 Terminated
9 enrolled 10 charts
Gynecologic

Neoplasm Metastasis, Endometrial Neoplasms

NCT04601857 2025-12-31

Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma

Taiho Oncology, Inc.

Phase 2 Terminated
43 enrolled 15 charts
Genitourinary

Advanced and Metastatic Urothelial Cancer

NCT04024436 2025-11-13

A Study of TAS-120 in Patients With Metastatic Breast Cancer

Taiho Oncology, Inc.

Phase 2 Terminated
64 enrolled 21 charts
Breast

Breast Neoplasms

NCT04189445 2025-10-08

Futibatinib in Patients With Specific FGFR Aberrations

Taiho Oncology, Inc.

Phase 2 Terminated
115 enrolled 19 charts
Gastrointestinal

Neoplasm Metastasis, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡